NEW YORK ( TheStreet) -- Novo Nordisk A/S (NYSE: NVO) hit a new 52-week high Tuesday as it is currently trading at $158.95, above its previous 52-week high of $158.20 with 97,243 shares traded as of 10:04 a.m. ET. Average volume has been 431,700 shares over the past 30 days.

Novo Nordisk A/S has a market cap of $89.56 billion and is part of the health care sector and drugs industry. Shares are up 34.9% year to date as of the close of trading on Monday.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 27.8 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Novo Nordisk A/S Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.